CA3065919A1 - Conjugues de construction d'anticorps - Google Patents

Conjugues de construction d'anticorps Download PDF

Info

Publication number
CA3065919A1
CA3065919A1 CA3065919A CA3065919A CA3065919A1 CA 3065919 A1 CA3065919 A1 CA 3065919A1 CA 3065919 A CA3065919 A CA 3065919A CA 3065919 A CA3065919 A CA 3065919A CA 3065919 A1 CA3065919 A1 CA 3065919A1
Authority
CA
Canada
Prior art keywords
immune
amino acid
conjugate
seq
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3065919A
Other languages
English (en)
Inventor
Peter Armstrong Thompson
Badreddin EDRIS
Craig Alan Coburn
Peter Robert Baum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARS Pharmaceuticals Inc
Original Assignee
Silverback Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silverback Therapeutics Inc filed Critical Silverback Therapeutics Inc
Publication of CA3065919A1 publication Critical patent/CA3065919A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Diverses compositions sont décrites. L'invention concerne également des compositions de conjugués composition-composé stimulateur immunitaire. L'invention concerne en outre les procédés de préparation et les utilisations de ces conjugués composition-composé stimulateur immunitaire. L'invention inclut des méthodes de traitement d'affections telles que le cancer.
CA3065919A 2017-06-07 2018-06-07 Conjugues de construction d'anticorps Abandoned CA3065919A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516667P 2017-06-07 2017-06-07
US62/516,667 2017-06-07
PCT/US2018/036560 WO2018227023A1 (fr) 2017-06-07 2018-06-07 Conjugués de construction d'anticorps

Publications (1)

Publication Number Publication Date
CA3065919A1 true CA3065919A1 (fr) 2018-12-13

Family

ID=64566685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065919A Abandoned CA3065919A1 (fr) 2017-06-07 2018-06-07 Conjugues de construction d'anticorps

Country Status (3)

Country Link
EP (1) EP3634401A1 (fr)
CA (1) CA3065919A1 (fr)
WO (1) WO2018227023A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111337685A (zh) * 2020-02-28 2020-06-26 苏州卫生职业技术学院 可溶性pd-l2作为sle生物标志物的应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018009916A1 (fr) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Conjugués d'adjuvant d'anticorps
WO2018067702A1 (fr) 2016-10-04 2018-04-12 Massachusetts Institute Of Technology Copolymères en forme de goupillon et leurs utilisations
CN111295389B (zh) * 2017-12-15 2021-10-22 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
AU2018385693A1 (en) * 2017-12-15 2020-06-18 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
JP2022505450A (ja) * 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
EP3920972A1 (fr) * 2019-02-07 2021-12-15 Sanofi Utilisation d'immunoconjugués anti-ceacam5 pour le traitement du cancer du poumon
EP3693023A1 (fr) * 2019-02-11 2020-08-12 Sanofi Utilisation d'immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon
WO2020190725A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
JP2022543086A (ja) 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
MX2022001812A (es) 2019-08-12 2022-03-11 Regeneron Pharma Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos.
US20210130473A1 (en) * 2019-10-09 2021-05-06 Silverback Therapeutics, Inc. TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF
US20210220391A1 (en) * 2020-01-10 2021-07-22 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
EP4106819A1 (fr) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Conjugués d'anticorps de nectine-4 et leurs utilisations
KR20220151630A (ko) * 2020-03-06 2022-11-15 다이이찌 산쿄 가부시키가이샤 신규 고리형 디뉴클레오티드 유도체를 포함하는 항체 약물 컨쥬게이트
CN116209678A (zh) 2020-07-01 2023-06-02 安尔士制药公司 抗asgr1抗体缀合物及其用途
EP4362976A1 (fr) 2021-07-02 2024-05-08 Merck Patent GmbH Anticorps et complexes anti-protac
CN113512117B (zh) * 2021-07-12 2023-08-22 武汉麦考津生物科技有限公司 一种可结合cd206的抗体及其应用
CN113563464B (zh) * 2021-08-01 2023-02-03 中国疾病预防控制中心性病艾滋病预防控制中心 人源化高中和活性抗新型冠状病毒单克隆抗体及应用
WO2023056069A1 (fr) * 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1006448B1 (pt) * 2009-03-25 2021-08-17 Genentech, Inc Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, micro­organismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
US20120064097A1 (en) * 2010-07-20 2012-03-15 Washburn Newell R Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates
SG11201701623UA (en) * 2014-09-12 2017-03-30 Genentech Inc Anti-her2 antibodies and immunoconjugates
WO2016168766A1 (fr) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Commutateurs de lymphocytes t porteurs d'un récepteur chimérique et leurs utilisations
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112018008918A8 (pt) * 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
CN109152843A (zh) * 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111337685A (zh) * 2020-02-28 2020-06-26 苏州卫生职业技术学院 可溶性pd-l2作为sle生物标志物的应用

Also Published As

Publication number Publication date
EP3634401A1 (fr) 2020-04-15
WO2018227023A1 (fr) 2018-12-13

Similar Documents

Publication Publication Date Title
CA3065919A1 (fr) Conjugues de construction d'anticorps
US20210115109A1 (en) Conjugates and methods of use thereof for selective delivery of immune-modulatory agents
ES2910365T3 (es) Nuevos polipéptidos biespecíficos contra CD137
US20230295325A1 (en) Novel anti-cd137 antibodies and uses thereof
US20190336615A1 (en) Tumor targeting conjugates and methods of use thereof
US20200199242A1 (en) Construct-peptide compositions and methods of use thereof
CA3168832A1 (fr) Anticorps cd28 a domaine unique et constructions multivalentes et multispecifiques de ceux-ci
TW201737941A (zh) 新穎的b7-h3-結合分子、其抗體藥物綴合物及其使用方法
JP2022512653A (ja) Ｐｄ－１単一ドメイン抗体およびその治療用組成物
EP3864044A1 (fr) Anticorps b7h3 à domaine unique et compositions thérapeutiques associées
JP2022500404A (ja) 置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用
EP3864045A2 (fr) Anticorps à domaine unique dll3 et compositions thérapeutiques
JP2022504826A (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
CN114341185A (zh) 抗间皮素抗体及其免疫缀合物
JP2023547380A (ja) 新規の抗ｌｉｌｒｂ２抗体および誘導体生成物
TW202309088A (zh) 新的穩定抗ｖｉｓｔａ抗體
US20220306752A1 (en) Epha2 antibodies
CA3146977A1 (fr) Constructions d'anticorps se liant a 4-1bb et recepteurs alpha de folate et leurs utilisations
CA3226306A1 (fr) Nouvelles molecules multi-specifiques
WO2023196869A1 (fr) Anticorps anti-epha2
WO2023094995A1 (fr) Anticorps humains cxcl16 et leur utilisation
JP2023518189A (ja) デルタ鎖媒介性免疫を調節するための材料及び方法
NZ787254A (en) Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301